When the US regulator said in December it could not complete its review of a submission for heart med inclisiran, a potential blockbuster, it came as something of a shock.
Now developer Novartis (NOVN: VX), a Swiss pharma giant, is cutting contractor Corden Pharma out of the loop in a bid to get the show back on the road.
The US Food and Drug Administration’s Complete Response Letter (CRL) indicated that unresolved questions related to Corden’s manufacturing site in Italy would prevent the target date of December 23 being met.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze